The first month on Mounjaro brings more than injections and a smaller appetite. Everyday questions come up too. What do you say when someone comments on your plate? How do you handle a symptom that worries you? What happens when food stops feeling as comforting as it used to? These questions deserve as much time at your follow-up visits as the number on the scale.
Mounjaro is a brand name for tirzepatide. Its U.S. label approves it for adults and children 10 and older with type 2 diabetes (Eli Lilly and Company, 2026a). The same medicine is sold as Zepbound for weight management in the United States, and in some other countries Mounjaro itself is also prescribed for weight loss. It is not a treatment for anxiety, depression, or an eating disorder. People respond to it in different ways, so talk through any mental health concerns with your own care team.
Easing Worry About Getting Started
Many people feel nervous before the first injection. If that is you, ask a pharmacist or your prescriber to walk you through the pen step by step. Find out which side effects to watch for and who to call if they happen. Clear answers to those two questions will help you more than trying to predict your first week from a friend’s story or an online forum.
Appetite, Food, and Mood
Changes in appetite are often the first thing people notice. They can also stir up feelings that have little to do with hunger, so it helps to look at each one on its own.
Less “Food Noise” Is Not the Same as Treated Anxiety
Some people say they have fewer constant thoughts about food, often called “food noise.” This is a personal experience, and there is no guarantee of when or whether it will happen. Feeling less hungry does not mean an anxiety disorder has been treated. And if thoughts about food keep coming, that is not a sign you have failed.
When Food Was Your Way to Unwind
If a favorite snack has been how you relax at the end of the day, losing interest in it can feel strange. Think about what you actually enjoyed in that moment. Was it the food itself, a break from work, or time with someone you care about? A phone call, some music, or a short walk may give you another way to relax. You can still enjoy food without feeling guilty, and it helps to notice when diet culture messages start telling you otherwise.
Remembering to Eat and Drink
When you feel less hungry, it is easy to skip a meal or go hours without a drink. A clinician or dietitian can help you find an eating routine that works, especially if nausea is limiting what you can eat. Eating as little as possible is not a measure of success. If restriction starts to feel driven by fear or guilt, mention it, since those patterns can overlap with eating disorders. Get advice right away if eating or drinking becomes difficult.
How Physical Side Effects Affect Your Mood
Stomach side effects are common with Mounjaro. Most nausea, vomiting, and diarrhea happen while the dose is being increased and tend to ease over time (Eli Lilly and Company, 2026a). Even so, they can make an ordinary day harder, and worrying about them adds to the strain.
| Common side effect | How it can affect your day |
| Nausea or vomiting | Can make meals feel like a chore and leave you drained |
| Diarrhea | Can cause fluid loss and make you anxious about being away from home |
| Constipation or stomach pain | Can cause ongoing discomfort that wears on your patience |
| Decreased appetite | Can make it easy to forget meals or drinks |
Note. Side effects from Eli Lilly and Company (2026a).
Losing fluids through vomiting or diarrhea can lead to dehydration, which can cause kidney problems, so drinking enough matters (Eli Lilly and Company, 2026b). The patient information that comes with your pen lists the known side effects. Tell your clinician about any that last, get worse, or bother you. Feeling unwell is something to get help with. It is not a test of how committed you are.
Check Physical Symptoms Before Calling Them Anxiety
Some physical symptoms feel a lot like nerves but have medical causes. Low blood sugar is a particular concern when Mounjaro is used with insulin or a sulfonylurea, a type of diabetes pill (Eli Lilly and Company, 2026a). The medication guide lists signs of low blood sugar that include sweating, shakiness, dizziness, confusion, a fast heartbeat, and even anxiety, irritability, or mood changes (Eli Lilly and Company, 2026b). Ask your care team about your own risk and what to do if these symptoms appear. Do not brush them off as “just nerves,” and do not change your diabetes medicines on your own.
Handling Comments at the Table
You can keep the details of your treatment private. If someone remarks on how much you are eating, a short reply such as “I’m comfortable with this amount, thank you” is often enough. It can also help to tell one trusted friend what you need before a meal. That way you have some support without having to explain yourself to everyone at the table.
Body Image Needs Its Own Support
Losing weight does not guarantee confidence, and it does not erase long-standing distress about how you look. If weighing yourself or checking your body over and over makes you anxious, ask your care team about a less stressful way to track your progress. You can work with a therapist at any point. There is no weight you have to reach before you deserve that help.
Taking Mood Changes Seriously
Regulators have looked closely at whether medicines in this class affect mood. In 2024, the UK’s Medicines and Healthcare products Regulatory Agency found that the evidence did not support a causal link between GLP-1 receptor agonists and depression, suicidal thoughts, or self-harm (Medicines and Healthcare products Regulatory Agency [MHRA], 2024). In January 2026, the U.S. Food and Drug Administration (FDA) reached a similar conclusion after reviewing trials with about 108,000 patients. It asked makers of weight-loss versions, including Zepbound, to remove the suicidal behavior and ideation warning from their labels (U.S. Food and Drug Administration [FDA], 2026).
A change in your own mood still deserves attention. Tell your prescriber about new or worsening anxiety, low mood, or changes in sleep, and keep taking your medicine as prescribed unless they tell you otherwise (FDA, 2026). Before you start treatment, let them know about any mental health care you already receive.
Short notes on your symptoms, meals, sleep, and injection dates can help you explain what has changed. They will not prove what caused a change, but they give your care team something concrete to work with. A guide on Mounjaro and anxiety also lists questions you can bring to your healthcare professional.
Making Room for Mental Health at Every Follow-Up
Keep your existing therapy and mental health appointments, and make sure your prescriber knows about every medicine you take. Get prompt professional help if distress is growing or getting in the way of daily life. If you feel unable to keep yourself safe, contact emergency services or a local crisis line right away.
The first month sets the tone for the rest of treatment. Use your follow-up visits to talk about how you are coping and how the medicine fits into your life, along with any physical symptoms. Your mood, your relationship with food, and your sense of yourself are all part of how well this treatment is working for you.
Sources
- Chaudry, E. (2025, April 16). Can Mounjaro cause anxiety and depression? Voy. https://www.joinvoy.com/blog/mounjaro-and-anxiety
- Eli Lilly and Company. (2026). Mounjaro (tirzepatide) injection: Highlights of prescribing information. https://uspl.lilly.com/mounjaro/mounjaro.html
- Eli Lilly and Company. (2026). Mounjaro (tirzepatide) injection: Medication guide (Revised August 2026). https://pi.lilly.com/us/mounjaro-us-mg.pdf
- Medicines and Healthcare products Regulatory Agency. (2024, September 4). MHRA finds evidence does not support a link between Glucagon-Like Peptide-1 (GLP-1) receptor agonists and suicidal and self-injurious thoughts and actions. GOV.UK. https://www.gov.uk/government/news/mhra-finds-evidence-does-not-support-a-link-between-glucagon-like-peptide-1-glp-1-receptor-agonists-and-suicidal-and-self-injurious-thoughts-and-act
- U.S. Food and Drug Administration. (2026, January 13). FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
Related Articles